One of the final hurdles in front of Amgen's $28 billion acquisition of Horizon Pharma has fallen after an agreement was reached between the two companies and the Federal
Horizon Pharma's executive vice president, head of research and development, and chief scientific officer talks to pharmaphorum about what inspires her in life sciences,
AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut